
Interview with Nicolas Ploquin in El Mundo
The company has a multidisciplinary team specialized in the construction, management and optimization of oncology facilities. It offers comprehensive turnkey projects tailored to each hospital, which may involve complete project management for the development of a new unit or the installation of complementary equipment in an existing unit.
Its work is very broad and ranges from unit design based on the center’s strategy, equipment selection and procurement, through project execution, day-to-day operations and financing. His goal is to improve patient care and quality of life by offering centers extensive clinical-practical knowledge, the best combination of tools and the optimization of their processes.
Today we talk to Nicolas Ploquin, CEO of Mercurius Health Group since the end of 2024.
Q: After four months in office, what are your impressions?
A: Excellent. Our team has a unique knowledge of the industry and the market, both in theory and clinical practice, and I am excited to contribute to its development.
We manage the projects and the day-to-day running of the centers we operate, with a vision to collaborate with our partners/clients in the common goal of improving the quality of life and outcomes of cancer patients. I am personally passionate about achieving this and fostering partnerships that enable state-of-the-art diagnostics and treatments.
Q: What path do you want Mercurius Health Group to take in this new phase?
A: The aging of the population in Europe and the increase in cancer make our services indispensable. Medical innovation demands bringing innovative and quality diagnostics and treatments to all cancer patients in Europe. I have been a patient myself, and this mission resonates deeply with me. We are leading the transformation toward innovation, operational efficiency and technological advancement to remain at the forefront of oncology treatment in Europe.
Q: What is the company’s intention regarding its presence in Spain?
A: We have developed a solid activity in Spain, with the start-up of the Institute of Advanced Radiosurgery (IRCA) and its innovative ZAP-X technology at the Viamed Santa Elena Hospital (Madrid), we manage the six CADPET Nuclear Medicine centers (PET TAC), and we have signed agreements with hospitals such as San Juan de Dios de Tenerife and Viamed Tarragona to incorporate and manage a comprehensive oncology unit in each of them. We are knowledgeable about the latest innovations and have agreements with all the leading manufacturers in the industry. This neutral position is key to be able to better advise our clients/partners.
Our intention is to continue to focus on clinical innovation and to implement our own operational method, based on people, processes and partners, to achieve maximum optimization and efficiency, and to ensure the highest quality standards in technology, processes and care.
Q: What about the centers you have in the rest of Europe?
A: We manage and support more than 15 locations in Europe. These include state-of-the-art centers such as WEGE Klinik, a renowned oncology hospital in Bonn (Germany), and the radiotherapy unit at SAMS Lisbon (Portugal). This allows the clinical, technical and management teams to always be up to date with the latest improvements in real projects.
You can read the article at: https://www.elmundo.es/economia/uestudio/2025/01/22/6790b53f21efa022328b4598.html
You can download the article in pdf here